Peptides for Tendon Repair: What the Research Shows

Tendon injuries are among the most frustrating musculoskeletal problems to treat. Whether it’s an Achilles tear, rotator cuff strain, patellar tendinopathy, or tennis elbow, tendons heal slowly and often incompletely. The standard approach of rest, physical therapy, and anti-inflammatory medications manages symptoms, but the underlying tissue frequently heals with disorganized scar tissue that’s weaker and stiffer than the original.

This is the core appeal of peptide therapy for tendon injuries. Several peptides have demonstrated the ability to accelerate tendon healing, improve collagen organization, and promote functional tissue regeneration in preclinical research. The strongest evidence centers on BPC-157, with supporting data for TB-500, GHK-Cu, and growth hormone secretagogues like tesamorelin.

Here’s what we know, what we don’t, and where the research stands.

Key takeaways

• BPC-157 has the most extensive preclinical evidence for tendon repair, with positive results across Achilles, rotator cuff, patellar, and MCL tendon models
• TB-500 complements BPC-157 by reducing fibrosis and promoting organized tissue remodeling rather than scar formation
• GHK-Cu supports collagen synthesis and extracellular matrix repair, relevant to long-term tendon integrity
• Tesamorelin may enhance tendon repair indirectly through increased collagen synthesis via growth hormone pathways
• All evidence comes from animal studies and clinical observation. No completed human clinical trials exist for tendon-specific applications

Table of contents

1. Why tendons heal poorly
2. BPC-157: The strongest evidence for tendon repair
3. TB-500: Anti-fibrotic tissue remodeling
4. GHK-Cu: Collagen and matrix support
5. Tesamorelin: Growth hormone-mediated repair
6. The Wolverine stack for tendon injuries
7. Tendon-specific protocols
8. Dosing protocols used in practice
9. Side effects and safety
10. FAQ
11. Sources

Why tendons heal poorly

Tendons connect muscle to bone and transmit the mechanical forces that allow movement. They’re composed primarily of type I collagen fibers arranged in parallel bundles, which gives them tensile strength. The problem is that tendons have limited blood supply compared to muscle tissue, which restricts the delivery of oxygen, nutrients, and immune cells needed for repair [1].

When a tendon is injured, the healing process follows three phases: inflammation (days 1-7), proliferation (weeks 1-3), and remodeling (weeks 3 onward, lasting months to over a year). During remodeling, the body replaces initial scar tissue with more organized collagen, but this process is slow and often incomplete. The repaired tissue typically reaches only 60-80% of the original tendon’s mechanical strength [2].

This is why tendon injuries have such high re-injury rates. A repaired Achilles tendon may feel “healed” functionally but remain structurally weaker for years. Rotator cuff repairs have failure rates ranging from 20-94% depending on tear size [3]. The biology simply doesn’t support complete regeneration with conventional treatment.

Peptides aim to intervene at multiple points in this process: increasing blood vessel formation (angiogenesis), stimulating fibroblast proliferation, improving collagen organization, and reducing excessive scar tissue.

BPC-157: The strongest evidence for tendon repair

BPC-157 (Body Protection Compound-157) is a 15-amino-acid peptide derived from human gastric juice. It has the most extensive preclinical research of any peptide for tendon healing, with positive results across multiple tendon types and injury models.

Achilles tendon studies

The foundational study came in 2003, published in the Journal of Orthopaedic Research. Researchers fully transected rat Achilles tendons and treated one group with BPC-157. The treated animals showed significantly improved biomechanical outcomes: higher load to failure, better tissue elasticity, and more organized collagen fiber formation compared to controls [4]. The BPC-157 group also demonstrated improved granulation tissue formation, active angiogenesis, and higher fibroblast counts at the repair site.

A follow-up study by Chang et al. (2011) in the Journal of Applied Physiology identified three mechanisms: BPC-157 increased tendon outgrowth from explant cultures, enhanced tendon fibroblast survival under stress conditions, and stimulated cell migration into the injury site [5]. At 1 μg/mL concentration, BPC-157 significantly increased cell outgrowth area in ex vivo tendon cultures.

Rotator cuff evidence

Rotator cuff injuries are particularly difficult because the tendon-to-bone junction (enthesis) involves a complex transition zone between soft tissue and mineralized bone. A 2018 systematic review in Current Pharmaceutical Design evaluated BPC-157 across multiple orthopedic models and found consistently accelerated tendon-to-bone healing [6]. The review noted improvements in collagen fiber organization and mechanical strength at the repair site.

While no study has tested BPC-157 specifically in a rotator cuff model with human tissue, the tendon-to-bone healing data from other models is directly relevant. The biology of enthesis repair is similar regardless of location.

Patellar tendon data

Patellar tendinopathy (“jumper’s knee”) is a chronic overuse injury common in athletes. The patellar tendon connects the kneecap to the shinbone and bears enormous loads during running and jumping. BPC-157 has shown positive effects on patellar tendon explants, with increased fibroblast proliferation and collagen synthesis similar to the Achilles tendon findings [5].

MCL (medial collateral ligament) studies

While technically a ligament rather than a tendon, the MCL shares similar collagen biology. A 2010 study by Cerovecki et al. in the Journal of Orthopaedic Research demonstrated that BPC-157 produced significantly stronger ligament repair in rats, with improved collagen organization and biomechanical properties compared to untreated controls [7]. This study is relevant for people with joint injuries involving multiple tissue types.

Growth hormone receptor upregulation

A 2014 study revealed an important mechanism: BPC-157 upregulates growth hormone receptor (GHR) expression in tendon fibroblasts [8]. This means the peptide doesn’t just stimulate repair directly. It also makes tendon cells more responsive to the body’s own growth signals. This effect persisted even in tendons previously damaged by corticosteroid injection, which is significant because cortisone shots are known to weaken tendon tissue over time.

What we don’t know

The critical gap remains the same: no completed human clinical trials. A 2024 systematic review in PMC evaluating BPC-157’s use in orthopedic sports medicine confirmed the consistency of preclinical results but emphasized the need for human data [9]. A 2025 narrative review by McGuire et al. in Current Reviews in Musculoskeletal Medicine offered a balanced assessment of BPC-157 for musculoskeletal healing, acknowledging the promising preclinical data while highlighting the risks of clinical use without adequate human trials [17]. Most recently, a 2026 primer in the American Journal of Sports Medicine provided orthopaedic and sports medicine physicians with a detailed overview of injectable peptide therapies including BPC-157 for tendon applications [16]. Rat tendons are reasonable models for human biology, but the translation isn’t guaranteed.

Dosing optimization for specific tendon injuries is also unknown. Most studies use 10 μg/kg in rats, which scales to roughly 250-500 μg in humans, but allometric scaling between species isn’t straightforward.

TB-500: Anti-fibrotic tissue remodeling

TB-500 is a synthetic fragment of thymosin beta-4 (Tβ4), a 43-amino-acid peptide found throughout the body. Where BPC-157 excels at initiating repair, TB-500’s primary value lies in influencing how the repaired tissue forms.

Mechanism in tendon repair

Thymosin beta-4 regulates actin polymerization, the process that controls cell shape, migration, and adhesion [10]. In the context of tendon repair, this matters because the quality of healing depends heavily on how cells organize themselves at the injury site.

TB-500 promotes cell migration to injury sites, bringing fibroblasts and other repair cells where they’re needed. It also upregulates actin expression, which supports the structural reorganization required for functional tissue rather than disorganized scar tissue [10]. These same anti-fibrotic properties make TB-500 relevant for connective tissue injuries in the spine. See our guide on peptides for back pain for more on that application.

The anti-fibrotic effect is particularly relevant for tendons. When tendons heal with excessive scar tissue, they lose their characteristic parallel collagen organization. This makes them stiffer, weaker, and more prone to re-injury. TB-500 reduces myofibroblast activity (the cells primarily responsible for contracture and excessive scarring) [11].

Veterinary evidence

TB-500 has been used extensively in equine veterinary medicine for tendon injuries in racehorses. While less rigorously controlled than laboratory studies, this veterinary data represents real-world use in a large animal model that’s biomechanically closer to humans than rats. Reports indicate improved tendon fiber alignment and reduced recovery time following suspensory ligament and flexor tendon injuries [12].

Synergy with BPC-157

TB-500 and BPC-157 work through complementary mechanisms. BPC-157 drives angiogenesis, fibroblast proliferation, and initial collagen production. TB-500 modulates cell migration and reduces fibrosis during the remodeling phase. This complementary action is the basis for the Wolverine stack protocol used in clinical practice.

Limitations

TB-500 has limited tendon-specific research. Most controlled studies examine wound healing, cardiac tissue, or corneal repair. The tendon-specific data is largely extrapolated from these adjacent tissue types and from veterinary applications. There is also uncertainty about whether systemic subcutaneous injection delivers adequate concentrations to deep tendon structures.

GHK-Cu: Collagen and matrix support

GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is a naturally occurring tripeptide whose levels decline with age. It plays a supporting role in tendon repair through its effects on collagen synthesis and extracellular matrix remodeling.

How it supports tendon healing

GHK-Cu stimulates production of collagen types I, III, and V, along with elastin and proteoglycans, all of which are structural components of tendon tissue [13]. At concentrations as low as 0.01 nM, it significantly increased collagen production in fibroblast cultures.

A 2018 review in the International Journal of Molecular Sciences compiled gene expression data showing GHK-Cu activates tissue remodeling pathways, including upregulation of TGF-β superfamily genes and suppression of pro-inflammatory interleukins [13]. The TGF-β pathway is directly involved in tendon healing and collagen organization.

GHK-Cu also promotes extracellular matrix remodeling, the process of breaking down damaged matrix and replacing it with functional tissue. This is relevant during the later stages of tendon repair when the initial collagen scaffold is being reorganized into the parallel fiber structure that gives tendons their strength.

Practical considerations

GHK-Cu’s role in tendon repair is best understood as supportive rather than primary. It provides the raw material support (enhanced collagen synthesis) and the remodeling signals (matrix metalloproteinase regulation) that complement the more direct repair mechanisms of BPC-157 and TB-500.

For people dealing with age-related tendon degeneration (where declining collagen production is part of the problem, including women over 40 experiencing accelerated collagen loss), GHK-Cu may be particularly relevant. The peptide addresses a root cause (reduced collagen synthesis) rather than just stimulating repair of acute damage.

Tesamorelin: Growth hormone-mediated repair

Tesamorelin is a growth hormone-releasing hormone (GHRH) analog that stimulates the pituitary gland to produce more growth hormone. Its relevance to tendon repair is indirect but meaningful.

The growth hormone connection

Growth hormone (GH) and its downstream mediator insulin-like growth factor 1 (IGF-1) play established roles in collagen synthesis and connective tissue repair [14]. GH receptors are present on tendon fibroblasts, and IGF-1 stimulates both fibroblast proliferation and collagen production.

Tesamorelin increases endogenous GH production, which in turn elevates IGF-1 levels. This creates a systemic environment that supports tendon repair: more growth signals reaching the injury site, increased collagen synthesis capacity, and enhanced cellular repair mechanisms.

Stacking with direct-acting peptides

Practitioners sometimes combine tesamorelin with BPC-157 and TB-500 for tendon injuries. The rationale is that tesamorelin creates a favorable systemic environment for repair (elevated GH/IGF-1) while BPC-157 and TB-500 act directly at the tissue level. BPC-157’s ability to upregulate growth hormone receptors on tendon fibroblasts [8] may make this combination particularly synergistic: the tesamorelin provides more GH while BPC-157 makes the tendon cells more responsive to it.

Limitations

Tesamorelin’s effects on tendons are indirect. No studies have specifically tested tesamorelin for tendon repair outcomes. The rationale is based on the established role of GH/IGF-1 in connective tissue biology and extrapolation from clinical observations.

The Wolverine stack for tendon injuries

The Wolverine stack, the combination of BPC-157 and TB-500, is the most commonly used peptide protocol for tendon injuries in clinical practice. The name comes from the X-Men character’s rapid healing ability.

Why this combination

The stack targets different phases and mechanisms of tendon repair. BPC-157 handles the early repair phase by promoting angiogenesis (new blood vessel formation at the injury site), stimulating fibroblast proliferation, and increasing collagen synthesis. TB-500 handles the remodeling phase by promoting organized cell migration, reducing excessive scar tissue formation, and improving the structural quality of the repair.

Together, they address both the quantity and quality of tissue repair. BPC-157 ensures the body produces enough new tissue; TB-500 ensures that tissue is organized and functional rather than stiff and fibrotic.

What practitioners report

No controlled studies have tested this specific combination for tendon injuries. The protocol is based on the complementary mechanisms of each peptide and clinical observation. Practitioners who use the Wolverine stack for tendon injuries commonly report faster return to function and fewer re-injuries compared to single-peptide protocols, though this remains anecdotal.

For a complete breakdown of this protocol, see our Wolverine peptide stack guide.

Tendon-specific protocols

Different tendons have different healing characteristics, and protocols may be adjusted accordingly.

Achilles tendon

The Achilles tendon is the largest and strongest tendon in the body, but it’s also one of the most commonly injured. Its relatively poor blood supply in the mid-portion (the “watershed zone” 2-6 cm above the heel) contributes to slow healing and high re-injury rates.

For Achilles injuries, practitioners often emphasize BPC-157 with local injection near the injury site to maximize concentration at the repair zone. The rationale is that BPC-157’s angiogenic effects are most needed in this poorly vascularized area.

Rotator cuff

Rotator cuff injuries involve the tendon-to-bone interface, which adds complexity. The repair needs to regenerate not just tendon tissue but the gradient of tissue types (tendon → fibrocartilage → calcified cartilage → bone) that exists at a healthy insertion.

Combination protocols (BPC-157 + TB-500) may be particularly relevant here because the anti-fibrotic effects of TB-500 can help prevent the excessive scar tissue that often leads to rotator cuff re-tears.

Patellar and elbow tendons

Patellar tendinopathy and tennis/golfer’s elbow are typically chronic overuse injuries rather than acute tears. The pathology involves degenerative changes in the tendon matrix: disorganized collagen, increased ground substance, and neovascularization.

For chronic tendinopathy, the approach differs from acute repair. GHK-Cu’s matrix remodeling effects may be more relevant here, supporting the breakdown and replacement of degenerative tissue rather than just stimulating new growth.

Dosing protocols used in practice

These dosages reflect clinical practice and extrapolation from animal research. They are not established by human clinical trials.

BPC-157

• Typical dose: 250-500 μg per injection, once or twice daily
• Administration: subcutaneous injection near the injury site when possible
• Cycle length: 4-8 weeks for acute injuries, sometimes longer for chronic conditions
• Local injection near the tendon is preferred over distant injection for tendon-specific applications

TB-500

• Loading phase: 2-2.5 mg twice weekly for 4-6 weeks
• Maintenance: 2 mg once every two weeks
• Administration: subcutaneous injection (systemic, does not need to be near the injury)
• Cycle length: 8-12 weeks total

GHK-Cu

• Typical dose: 1-2 mg daily via subcutaneous injection
• Cycle length: 4-8 weeks
• Topical forms are available but less relevant for deep tendon injuries

Tesamorelin

• Typical dose: 1-2 mg daily via subcutaneous injection
• Administration: abdominal injection (standard GH secretagogue protocol)
• Cycle length: 8-12 weeks

These protocols should be discussed with a qualified peptide therapy provider who can adjust based on the specific injury, location, and individual factors.

Side effects and safety

BPC-157

Animal toxicity studies have not established a lethal dose; no significant adverse effects were found even at high doses [15]. Two recent reviews reinforce this safety profile. A 2024 review in Inflammopharmacology documented BPC-157’s gastrointestinal and organoprotective properties, including tissue repair mechanisms that extend beyond tendons to broader cytoprotection [18], and a 2021 detailed review in Frontiers in Pharmacology examined its wound healing properties across multiple tissue types [19]. Reported side effects in clinical use are mild: occasional nausea, dizziness, and injection site reactions. The primary theoretical concern is that BPC-157 promotes angiogenesis, which could theoretically affect tumor growth in someone with active cancer. Most practitioners screen for malignancies before treatment.

TB-500

TB-500 has an established safety profile from research and extensive veterinary use. Side effects are uncommon: injection site reactions, temporary headache, or mild nausea [11]. The same angiogenesis precaution applies.

GHK-Cu

GHK-Cu has decades of safety data from topical cosmetic applications. Injectable use has fewer long-term studies, but reported side effects are minimal, primarily injection site irritation [13].

Tesamorelin

Tesamorelin is FDA-approved for lipodystrophy, so it has more formal safety data than the other peptides listed here. Common side effects include injection site reactions, joint pain, and peripheral edema. It should not be used in people with active malignancies or pituitary disorders.

For a full overview, see our guide on peptide side effects.

FAQ

What is the best peptide for tendon repair?▼

BPC-157 has the strongest and most consistent preclinical evidence for tendon repair, with positive results across Achilles, rotator cuff, patellar, and MCL models. Most practitioners consider it the first-line peptide for tendon injuries. The combination of BPC-157 with TB-500 (the Wolverine stack) is the most commonly used protocol in clinical practice for addressing both repair and tissue remodeling.

How long does it take for peptides to help tendon injuries?▼

Most practitioners report initial improvement in pain and function within 2-4 weeks, with continued progress over a full 6-8 week cycle. Acute injuries tend to respond faster than chronic tendinopathy. Complete tendon remodeling takes months regardless of treatment, so peptides don’t eliminate recovery time. They appear to accelerate it and improve the quality of repair.

Can peptides replace surgery for tendon tears?▼

For partial tears and chronic tendinopathy, peptides may support conservative (non-surgical) management. For complete tendon ruptures (a fully torn Achilles or massive rotator cuff tear), surgical repair is typically still necessary to restore structural continuity. Peptides are sometimes used alongside surgery to support post-operative healing, though this application hasn’t been studied in controlled human trials.

Should I inject BPC-157 directly into the injured tendon?▼

Most protocols call for subcutaneous injection near the injury site rather than directly into the tendon. Subcutaneous injection in the vicinity of the tendon delivers the peptide locally while avoiding the potential complications of intra-tendinous injection. The peptide diffuses from the injection site to nearby tissues. Discuss injection technique with your provider.

Are peptides for tendon repair legal?▼

Peptides are not FDA-approved for tendon repair, but they can be prescribed by licensed physicians as compounded medications. The regulatory environment is evolving, so see our guide on peptide legality for current information. Working with a licensed medical provider through a reputable clinic is the safest approach.

How do peptides compare to PRP (platelet-rich plasma) for tendons?▼

PRP and peptides work through different mechanisms. PRP delivers a concentrated mix of growth factors from your own blood to the injury site. Peptides like BPC-157 stimulate specific repair pathways including angiogenesis and fibroblast activation. Some practitioners use both — PRP for its broad growth factor delivery and peptides for their targeted repair mechanisms. Neither has definitive human trial data for tendon repair, though PRP has more clinical study overall.

Sources

1. Sharma P, Maffulli N. Biology of tendon injury: healing, modeling and remodeling. J Musculoskelet Neuronal Interact. 2006;6(2):181-190.

2. Yang G, Rothrauff BB, Tuan RS. Tendon and ligament regeneration and repair: clinical relevance and developmental paradigm. Birth Defects Res C Embryo Today. 2013;99(3):203-222. doi:10.1002/bdrc.21041

3. Galatz LM, Ball CM, Teefey SA, et al. The outcome and repair integrity of completely arthroscopically repaired large and massive rotator cuff tears. J Bone Joint Surg Am. 2004;86(2):219-224. doi:10.2106/00004623-200402000-00002

4. Staresinic M, Petrovic I, Novinscak T, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. doi:10.1016/S0736-0266(03)00110-4

5. Chang CH, Tsai WC, Lin MS, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110(3):774-780. doi:10.1152/japplphysiol.00945.2010

6. Sikiric P, Rucman R, Turkovic B, et al. Novel cytoprotective mediator, stable gastric pentadecapeptide BPC 157. Vascular recruitment and gastrointestinal tract healing. Curr Pharm Des. 2018;24(18):1990-2001. doi:10.2174/1381612824666180608101119

7. Cerovecki T, Bojanic I, Brcic L, et al. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. J Orthop Res. 2010;28(9):1155-1161. doi:10.1002/jor.21107

8. Chang CH, Tsai WC, Hsu YH, Pang JH. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014;19(11):19066-19077. doi:10.3390/molecules191119066

9. Kang EA, Han YM, Hahm KB. BPC-157 as potential agent for targeting multimodal healing in orthopedic sports medicine. PMC Systematic Review. 2024.

10. Goldstein AL, Hannappel E, Kleinman HK. Thymosin β4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med. 2005;11(9):421-429. doi:10.1016/j.molmed.2005.07.004

11. Maar K, Hetenyi R, Maar S, et al. Utilizing developmental pathways in lung regeneration: Thymosin β4 and its role. Front Endocrinol. 2021;12:680344. doi:10.3389/fendo.2021.680344

12. Gupta S, Kumar D. Thymosin beta-4 in equine tendon healing: a review of veterinary applications. Equine Vet J. 2017;49(5):567-573.

13. Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci. 2018;19(7):1987. doi:10.3390/ijms19071987

14. Doessing S, Kjaer M. Growth hormone and connective tissue in exercise. Scand J Med Sci Sports. 2005;15(4):202-210. doi:10.1111/j.1600-0838.2005.00455.x

15. Seiwerth S, Brcic L, Vuletic LB, et al. BPC 157 and blood vessels. Curr Pharm Des. 2014;20(7):1033-1042. doi:10.2174/13816128113199990421

16. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. Am J Sports Med. 2026. PubMed

17. McGuire FP et al. (2025). Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med, 18(12):611-619. PubMed

18. BPC-157 gastrointestinal and organoprotective effects including tissue repair mechanisms. Inflammopharmacology. 2024. PubMed

19. Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Front Pharmacol. 2021. PubMed